Role of lactoferrin in the treatment of E. coli-induced bovine mastitis
- PMID: 40201807
- PMCID: PMC11974306
- DOI: 10.5455/OVJ.2025.v15.i2.44
Role of lactoferrin in the treatment of E. coli-induced bovine mastitis
Abstract
Background: Bovine mastitis (BM) is a costly disease in the dairy industry. It is associated with reduced milk production and changes in milk composition and quality. Escherichia coli is the most important pathogen causing BM.
Aim: This study aimed to assess the efficacy of lactoferrin (LF) as an enhanced agent when combined with marbofloxacin for the treatment of E. coli BM.
Methods: Eighty lactating cattle and buffaloes, 40 each, aged 4-6 years suffering from BM underwent clinical examination. Milk samples were collected for bacteriological examination. The recovered E. coli isolates were subjected to serological, and polymerase chain reaction (PCR) analysis. BM cases were allocated into two groups: group (A) was treated with marbofloxacin combined with LF, and group (B) was treated with marbofloxacin alone.
Results: Fifty E. coli isolates were recovered. Six serogroup were identified: O55, O103, O26, O11, O44, and O124. All isolates were sensitive to marbofloxacin, while there was resistance to gentamycin and ampicillin (26% each), cefquinome (14%), cefixime (10%), and SuLFamethoxazole and trimethoprim (4%). The molecular identification of E. coli strains revealed that the 16S rRNA gene was present in all identified E. coli strains (100%). All isolates resistant to antibiotics encoded BlaTEM, aadB, and Sul1, whereas the qnrS gene was not detected in any E. coli isolate. The broth dilution method did not detect growth when the marbofloxacin (6 μg/ml) was combined with LF (2 mg/ml). Group (A) showed significant improvements compared with group (B), with no recurrence rate.
Conclusion: LF can serve as a significant cotreatment agent for treating BM. As antibiotic resistance increases, LF-based drugs could play an important role in providing sustainable, effective alternatives for dairy animals.
Keywords: Bovine mastitis; E. coli; Lactoferrin; Marbofloxacin.
Conflict of interest statement
None.
Figures

Similar articles
-
Molecular Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Milk Samples of Dairy Cows with Mastitis in Bavaria, Germany.Microb Drug Resist. 2018 May;24(4):505-510. doi: 10.1089/mdr.2017.0182. Epub 2017 Sep 27. Microb Drug Resist. 2018. PMID: 28953418
-
[Current resistance status of Escherichia coli strains from bovine mastitis milk samples].Schweiz Arch Tierheilkd. 1997;139(11):495-9. Schweiz Arch Tierheilkd. 1997. PMID: 9480542 German.
-
The efficacy of bovine lactoferrin in the treatment of cows with experimentally induced Escherichia coli mastitis.J Vet Pharmacol Ther. 2004 Aug;27(4):197-202. doi: 10.1111/j.1365-2885.2004.00581.x. J Vet Pharmacol Ther. 2004. PMID: 15305847 Clinical Trial.
-
Utilization of lactoferrin to fight antibiotic-resistant mammary gland pathogens.J Anim Sci. 2008 Mar;86(13 Suppl):66-71. doi: 10.2527/jas.2007-0216. Epub 2007 Jun 12. J Anim Sci. 2008. PMID: 17565052 Review.
-
[Escherichia coli mastitis in cattle. III. Antibacterial therapy].Tijdschr Diergeneeskd. 1989 Sep 15;114(18):939-48. Tijdschr Diergeneeskd. 1989. PMID: 2678591 Review. Dutch.
References
-
- Abd-ELFatah E.B., El-Emam A., Mohamed M., Shehata A.A., Elsheikh H.E., Bakrash M.M. Assessment of potential treatments for clinical mastitis caused by Escherichia coli in cattle using clinical and biochemical markers. Benha. Vet. Med. J. 2024;47(1):5–11.
-
- Al Habty S.H., Ali D.N. Efficiency of lactoferrin to eradicate multidrug resistant Staphylococcus aureus isolated from some dairy products. Adv. Anim. Vet. Sci. 2023;11(1):35–44.
-
- Ali M., Ahmad M., Muhammad K., Anjum A. Prevalence of sub-clinical mastitis in dairy buffaloes of Punjab, Pakistan. J. Anim. Plant. Sci. 2011;21(3):477–480.
-
- Andrews J.M. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 2001;48(1):5–16. - PubMed
-
- Arabi H., Pakzad I., Nasrollahi A., Hosainzadegan H., Jalilian F.A., Taherikalani M., Samadi N., Sefidan A.M. Sulfonamide resistance genes (sul) m in extended spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli isolated from Iranian hospitals. Jundishapur. J. Microbiol. 2015;8(7):e19961. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials